Matthias Bureik
School
School of Pharmaceutical Science and Technology
Professional Title
Professor
Discipline
Molecular and Cellular Pharmacology
Contact Information
15522686706
matthias@tju.edu.cn
Room A506B, Building 24, Tianjin University
Education Background
- Doctoral degree| Saarland University Med. School, Homburg, Germany| Medical Biochemistry | 1997
- Postdoctoral | Saarland University, Germany| Biochemistry| 2000
- Master’s Degree| Saarland University, Germany| Science Chemistry | 1994
Research Interests
- A primary aim is to search for compounds that can act as CYP4Z1-activated prodrugs (right figure) and have potential for treatment of breast cancer.
- In addition, additional substrates of this enzyme that are both structurally different and far better suited to screening procedures than fatty acids have been identified
- This is expected to aid doctors in choosing the correct dosage for patients. In the second area, the group has successfully identified CYP4Z1 to be a fatty acid in-chain hydroxylase.
- A primary goal in the first area involves systematic testing of all variants of drug metabolizing cytochrome P450 enzymes (CYPs or P450s; see left figure below) and UDP glycosyltransferases (UGTs) identified in Chinese patients.
- 2) investigation of human CYP4Z1 and the treatment of breast cancer.
- 1) Human drug metabolizing enzymes
Positions & Employments
-
2012.9-2014.6
Department of Biochemistry, Saarland University, Germany | Lecturer & Senior Scientist -
2008.9-2012.6
PomBioTech GmbH, Germany | CEO -
2004.9-2008.6
Department of Biochemistry, Saarland University, Germany | Senior Scientist (C2) -
2001.9-2004.6
Department of Biochemistry, Saarland University, Germany | Senior Scientist (C1)
Academic Achievements
- Books
- [1] Neunzig I., C.-A. Dragan, M. Widjaja, A.E. Schwaninger, F.T. Peters, H.H. Maurer & M. Bureik (2011) Whole-cell Biotransformation Assay for Investigation of the Human Drug Metabolizing Enzyme CYP3A7. Biochim Biophys Acta 1814, 161-167.
- [2] Dragan C.-A., F.T. Peters, P. Bour, A.E. Schwaninger, S.M. Schaan, I. Neunzig, M. Widjaja, J. Zapp, T. Kraemer, H.H. Maurer & M. Bureik (2011) Convenient Gram-Scale Metabolite Synthesis by Engineered Fission Yeast Strains Expressing Functional Human P450 Systems. Appl Biochem Biotechnol 163, 965-980.
-
- [3] Naumann J.M., A. Zöllner, C.-A. Dragan, J. Messinger, J. Adam & M. Bureik (2011) Biotechnological production of 20α-dihydrodydrogesterone at pilot scale. Appl Biochem Biotechnol 165, 190-203.
- [4] Buchheit D., E.I. Schmitt, D. Bischoff, T. Ebner & M. Bureik (2011) S-Glucuronidation of 7-mercapto-4-methylcoumarin by human UDP glycosyltransferases in genetically engineered fission yeast cells. Biol Chem 392, 1089-95.
- [5] Parr, M.K., A. Zöllner, G. Fusshöller, G. Opfermann, N. Schlörer, M. Zorio, M. Bureik & W. Schänzer (2012) Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - Insights from metandienone metabolism. Toxicol Lett. 213, 381-391.
- [6] Neunzig, I., M. Widjaja, F.T. Peters, H.H. Maurer, A. Hehn, F. Bourgaud & M. Bureik (2013) Coexpression of CPR from various origins enhances biotransformation activity of human CYPs in S. pombe. Appl Biochem Biotechnol. 170, 1751-1766.
- [7] Klein, T., S. Lange, N. Wilhelm, M. Bureik, T.H. Yang, E. Heinzle & K. Schneider (2014) Overcoming the metabolic burden of protein secretion in Schizosaccharomyces pombe - A quantitative approach using C-13-based metabolic flux analysis. Metab Eng. 21, 34-45.
- [8] Weyler C, M. Bureik & E. Heinzle (in press) Selective oxidation of UDP-glucose to UDP-glucuronic acid using permeabilized Schizosaccharomyces pombe expressing human UDP-glucose 6-dehydrogenase. Biotechnol Lett.
- [9] Neunzig, I.; Göhring, A.; Dragan, C.-A.; Zapp, J.; Peters, F. T.; Maurer, H. H.; Bureik, M. Production and NMR analysis of the human ibuprofen metabolite 3-hydroxyibuprofen. 2012, J. Biotechnol. 157, 417.
- [10] Neunzig, I.; Widjaja, M.; Dragan, C.-A.; Peters, F. T.; Maurer, H. H.; Bureik, M. Engineering of human CYP3A enzymes by combination of activating polymorphic variants. Appl. Biochem. Biotechnol. 2012, 168, 785.
- [11] Buchheit, D.; Dragan, C.-A.; Schmitt, E. I.; Bureik, M. Production of Ibuprofen Acyl Glucosides by Human UGT2B7. Drug Metab Dispos 2011, 39, 2174.
- [12] Zöllner A.; Buchheit, D.; Meyer, M. R.; Maurer, H. H.; Peters, F. T.; Bureik, M. Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. Bioanalysis 2010, 2, 1277. (Review)
- [13] Zöllner, A.; Dragan, C.-A.; Pistorius, D.; Müller, R.; Bode, H. B.; Peters, F. T.; Maurer, H. H.; Bureik, M. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol. Chem. 2009, 390, 313.
- [14] Naumann J.M., G. Küttner & M. Bureik (2011) Expression and Secretion of a CB4-1 scFv-GFP Fusion Protein by Fission Yeast. Appl Biochem Biotechnol 163, 80-9.
- Patents
- [1] Bureik, M. & R. Bernhardt, Produktion von Steroidhormonen durch rekombinante Spalthefen. 1998, DE 19826821.
- [2] Bernhardt, R., A. Bichet, M. Bureik & N. Lenz, Der "Bringer" - eine hocheffiziente Methode zur Erzeugung von Mutantenbibliotheken. 2002, DE 10260977.
-
- [3] Hartmann, R.W., S. Ulmschneider, U. Muller-Vieira, M. Bureik & R. Bernhardt, Selektive Hemmstoffe der Aldosteronsynthase (CYP11B2) zur Behandlung der Herzinsuffizienz und Myokardfibrose. 2004, DE 102004035322.
- [4] Dragan, C.-A., D. Buchheit & M. Bureik, Drug metabolism. 2008, WO/2010/031875.
- [5] Zöllner, A. & M. Bureik, Methods for identifying potential CYP4 metabolites, inhibitors or prodrugs. 2008, WO/2010/040770.
- [6] Bureik M., T. Hakki & R. Bernhardt, Verwendung von Inhibitoren der Aldosteron-Synthase zur Behandlung von Hyperaldosteronismus und Herz-Kreislauf-Erkrankungen. 2009, DE102009044375.
- [7] Bureik M., C.-A. Dragan & A. Dragan, Method of generating HCV-derived virus-like particles. 2009, WO/2011/042551.
- [8] Bureik, M., J.M. Naumann & C.-A. Dragan, Method for the production of Sweet Proteins. 2010, WO/2011/124463.
- Honors & Awards
- [1] 2005 – German business magazine impulse: PomBioTech was named as one of the 25 most promising start-up companies in Germany. The award address was given by Wolfgang Clement, then German Federal Minister of Economics and Labour.
- [2] 2011 – PomBioTech was selected as a finalist for Red Herring's Top 100 Europe award.
-
- [3] 2005 – German business magazine impulse: PomBioTech was named as one of the 25 most promising start-up companies in Germany. The award address was given by Wolfgang Clement, then German Federal Minister of Economics and Labour.
- [4] 2011 – PomBioTech was selected as a finalist for Red Herring's Top 100 Europe award.
- [5] 2005 – German business magazine impulse: PomBioTech was named as one of the 25 most promising start-up companies in Germany. The award address was given by Wolfgang Clement, then German Federal Minister of Economics and Labour.
- [6] 2011 – PomBioTech was selected as a finalist for Red Herring's Top 100 Europe award.